Compare Illumina, Inc. (ILMN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs BlackRock TCP Capital Corp — how do they compare? Illumina, Inc. trades at $278 (market cap $39.95B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M). The key difference: Illumina, Inc. is far larger — about 118.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and BlackRock TCP Capital Corp for 88 Days on average.
| ILMN | TCPC | |
|---|---|---|
Market Cap | $39.95B | $337.71M |
Volume | 3,169,503 | 436,109 |
Sector | Health | Financials |
52-Week High | $293.69 | $6.20 |
52-Week Low | $91.00 | $3.13 |
Typical Hold Time | 83 Days | 88 Days |
Enterprise Value | $41.31B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
TCPC trades at $4.01, up 1.78% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.22, beating expectations, and announced a $523 million portfolio sale to reduce leverage. Despite negative revenue and net income trends, the stock trades at a discount to book value with a P/B of 0.61. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to declining revenue and negative profitability metrics, though strategic portfolio sales and dividend payments provide some stability. Key risks include ongoing net losses and class action litigation, while institutional sentiment appears mixed with technical indicators suggesting near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
